Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Atom Therapeutics' Gout Drug Shows Promise in Phase 2b/3 Trial

Atom Therapeutics, a Chinese biotech company, has announced positive results from a phase 2b/3 study of its oral URAT1 inhibitor, lingdolinurad (ABP-671), for the treatment of gout. The trial, conducted across multiple continents, met all primary and secondary endpoints, positioning the drug as a potential best-in-class therapeutic in the gout treatment landscape.

NoahAI News9/9/2025

AI-Powered Patient Communication Startup Hello Patient Secures $22.5M in Series A Funding

Hello Patient, a startup leveraging generative artificial intelligence (AI) to handle patient communications for medical practices, has raised $22.5 million in a Series A funding round. The investment, led by Scale Venture Partners with participation from 8VC, Bling Capital, Max Ventures, Remus Capital, and FirstLook Partners, values the company at $100 million.

NoahAI News9/9/2025

LB Pharmaceuticals Aims for $228M IPO to Fund Late-Stage Schizophrenia Study

LB Pharmaceuticals, a CNS-focused biotech company, has announced plans for an initial public offering (IPO) targeting $228.5 million in funding. The move comes as a potential breakthrough in the stagnant biotech IPO market, which has seen no activity since February.

NoahAI News9/9/2025

Ayble Health Partners with Castlight to Expand Access to Digestive Care Solutions

Ayble Health, a virtual provider specializing in digestive conditions, has announced a groundbreaking partnership with Castlight Health, a leading benefits navigation platform. This collaboration marks a significant step in addressing the growing need for accessible and effective gastrointestinal (GI) care solutions in the workplace.

NoahAI News9/9/2025

Supreme Court Allows Temporary Removal of FTC's Democratic Commissioner

The Supreme Court has issued a temporary stay allowing the removal of Rebecca Kelly Slaughter, one of the Federal Trade Commission's (FTC) Democratic commissioners, marking a significant shift in the agency's composition and potentially its regulatory approach. This development comes amid ongoing legal battles and policy changes that could reshape the pharmaceutical and healthcare landscapes.

NoahAI News9/9/2025

Takeda and Alkermes Unveil Promising Data for Narcolepsy Treatments at World Sleep 2025

In a significant development for narcolepsy treatment, pharmaceutical giants Takeda and Alkermes have presented compelling data for their respective orexin receptor 2 (OX2R)-selective agonists at the World Sleep 2025 Congress in Singapore. These revelations mark a crucial step forward in the race to bring a new class of narcolepsy drugs to market, potentially transforming care for patients suffering from this chronic sleep disorder.

NoahAI News9/8/2025

Obesity Drug Development Accelerates with Digital Innovation and Patient-Centered Approaches

In a rapidly evolving pharmaceutical landscape, obesity drug development has emerged as a focal point for innovation and investment. With over $30 billion invested globally in 2024, sponsors are redefining trial design and execution to meet the complex demands of obesity research.

NoahAI News9/8/2025

Integrated Biomarker Testing Drives Precision Oncology Development

Biomarker testing is revolutionizing targeted and immunotherapy development in oncology, offering a pathway to accelerate research, improve patient stratification, and reduce trial risk. As the pharmaceutical industry increasingly focuses on precision medicine, integrated biomarker strategies are becoming essential for therapy differentiation and streamlined regulatory approvals.

NoahAI News9/8/2025

Smith+Nephew Enhances Evidence Generation Through Integrated Clinical and Medical Affairs Approach

In a strategic move to optimize product development and improve patient outcomes, Smith+Nephew has implemented a highly integrated organizational structure that aligns its clinical and medical affairs functions. This approach, detailed by Matt Christensen, Senior Vice President of Global Clinical and Medical Affairs, aims to break down silos and foster collaboration across various departments, ultimately leading to more efficient evidence generation and product launches.

NoahAI News9/8/2025

Junshi Biosciences Reports Positive Phase 3 Results for IL-17 Psoriasis Drug

Junshi Biosciences, a Shanghai-based pharmaceutical company, has announced successful phase 3 trial results for its interleukin-17 (IL-17) antibody in treating moderate to severe plaque psoriasis. The positive outcome sets the stage for the company to pursue regulatory approval in China, potentially introducing a new treatment option for millions of patients.

NoahAI News9/8/2025

WellSpan Health and General Catalyst Expand Partnership to Advance AI in Healthcare

WellSpan Health, a Pennsylvania-based health system, has announced a significant expansion of its partnership with venture capital firm General Catalyst to co-develop and implement artificial intelligence (AI) technologies in healthcare. This collaboration marks a major step forward in the integration of AI solutions within a real-world healthcare setting.

NoahAI News9/8/2025

Summit's PD-1xVEGF Drug Shows Mixed Results in Global Trial, Raising Questions About Regional Consistency

Summit Therapeutics' closely watched PD-1xVEGF antibody, ivonescimab, has yielded mixed results in its first global phase 3 trial, challenging claims of regional consistency while still offering a glimmer of hope for potential approval. The detailed data, presented at the 2025 World Conference on Lung Cancer, paint a complex picture of the drug's performance across different patient populations.

NoahAI News9/7/2025

«1...64 65 66 67